sarcoma
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech) for subcutaneous injection ...
SEPTEMBER 16, 2024
FDA Grants Accelerated Approval to Tecelra for Unresectable or Metastatic Synovial Sarcoma
The FDA has granted accelerated approval to afamitresgene autoleucel (Tecelra, Adaptimmune LLC), a ...
AUGUST 2, 2024
FDA Approves Nirogacestat for Desmoid Tumors
The FDA approved nirogacestat (Ogsiveo, SpringWorks Therapeutics) for adult patients with progressing desmoid ...
NOVEMBER 28, 2023
Risk Score Helps Guide Patient Selection for Resection of Sarcoma Lung Metastases
On the basis of preoperative characteristics, a novel risk score that stratifies patients with pulmonary metastases ...
NOVEMBER 24, 2020
Neoadjuvant Combo Beneficial in Soft Tissue Sarcoma
In soft tissue sarcomas of the trunk or extremities, a neoadjuvant chemotherapy combination of epirubicin plus ...
MARCH 29, 2017
For STS Patients With Metastases at Time of Dx, Metastasectomy May Improve Outcomes
Metastasectomy should be strongly considered for patients with extremity soft tissue sarcomas who present with ...
NOVEMBER 22, 2016
New Data Remind Clinicians of Poor Outcomes With Uterine Sarcoma Morcellation
Investigators are urging clinicians to strongly consider the risk of morcellating supposedly benign uterine myomas
NOVEMBER 22, 2016
Chemotherapy Recommended for Radiation-Induced Sarcomas
Chemotherapy improved outcomes in a small group of patients who developed central nervous system sarcomas after ...
NOVEMBER 22, 2016
Outcomes Similar for Old and Young Patients Undergoing Surgery for Retroperitoneal Sarcoma
Older patients who undergo multivisceral resection for retroperitoneal sarcoma may be more likely than younger ...
NOVEMBER 22, 2016
Findings Favorable for Multikinase Inhibitor Regorafenib
Regorafenib found effective for leiomyosarcoma, synovial sarcoma and other nonadipocytic STSs.
OCTOBER 28, 2016
Tivozanib Promising for Some Soft Tissue Sarcomas
Tivozanib, a tyrosine kinase inhibitor that had previously failed to receive FDA approval for the treatment of ...
OCTOBER 27, 2016
Lymphadenectomy Unnecessary in Most Uterine Sarcomas
Routine lymphadenectomy does not significantly improve outcomes in patients with uterine leiomyosarcoma and ...
OCTOBER 25, 2016